Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - Should You Buy?

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) saw an uptick in trading volume on Monday . 3,133,669 shares were traded during mid-day trading, an increase of 259% from the previous session's volume of 873,369 shares.The stock last traded at $22.40 and had previously closed at $24.14.

Analyst Ratings Changes

Several research firms have recently commented on GMAB. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S currently has an average rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Trading Up 3.0 %

The stock has a market cap of $13.60 billion, a P/E ratio of 11.81, a PEG ratio of 2.65 and a beta of 0.98. The company's 50-day simple moving average is $21.26 and its 200 day simple moving average is $22.50.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC increased its position in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the period. Barclays PLC lifted its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC grew its stake in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.